NASDAQ:SWAV - Nasdaq - US82489T1043 - Common Stock - Currency: USD
We also talk with Sean Milliken, managing director of The Motley Fool Foundation’s ImpactFool (IF) Fund.
Looking beyond the headlines creates an opportunity for investors who have the patience to seek must-own overlooked stocks.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.
Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.
Mentions: JNJ
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ShockWave Medical (NASDAQ:SWAV) just reported results for the first quarter of ...
SWAV stock results show that ShockWave Medical beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of...
Mentions: JNJ
The healthcare behemoth has fortified its dividend.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The value of the “global medical device market” is expected to jum...
The medical device market is growing fast, and top medical device firms can become takeover targets. Here are three medtech stocks to watch.
Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder.
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.
These stocks to buy have enjoyed big rallies and the gains look likely to continue in coming months even if the market does peak.
These three dividend kings are among the most reliable dividend stocks, and each has at least one strong buy rating.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Mentions: AIRC
Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina ...
Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina